Merck's Keytruda plus TIGIT combo proves less effective than chemo in open-label lung cancer study

Max Gelman

Senior Editor

Ahead of Keytruda’s patent cliff in 2028, Merck is trying to develop a variety of combination therapies that can extend the megablockbuster’s potential. But one …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck's Keytruda plus TIGIT combo proves less effective than chemo in open-label lung cancer study

Max Gelman

Senior Editor

Sign up to read this article for free.

FDA approves subcutaneous version of Bristol Myers' Opdivo

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

Exclusive: Florida cancer biotech raises $100M Series A

CagriSema’s weight loss data disappointed. What does Novo do next?

Mer­ck­'s Keytru­da plus TIG­IT com­bo proves less ef­fec­tive than chemo in open-la­bel lung can­cer study

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Merck's Keytruda plus TIGIT combo proves less effective than chemo in open-label lung cancer study

FDA approves subcutaneous version of Bristol Myers' Opdivo

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

Exclusive: Florida cancer biotech raises $100M Series A

CagriSema’s weight loss data disappointed. What does Novo do next?